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Abstract
Background: To estimate the prevalence of lymphedema/chronic edema (CO) and wounds in acute hospital
inpatients in five different countries.
Methods and Results: A point-prevalence study was carried out during working day periods in six general
hospitals in four countries (Denmark, France, United Kingdom, and Australia) and one hospital oncology
inpatient unit in one other country (Ireland). The study used validated clinical tools for the assessment and
collection of data. Data were collected by expert clinicians through interviews and physical examination of the
patients present in the wards. A total of 1905 patients could be included and investigated among the 3041 total
bed occupancy in the seven hospitals. Lymphedema/CO was present in 723 of them (38%). Main risk factors
associated with CO were age, morbid obesity, and heart failure, as well as chair bound immobility and
neurological deficiency. History of cellulitis was frequent in patients with CO and wounds (24.8%) and CO
alone (14.1%) compared to the 1.5% prevalence in patients without CO.
Conclusion: Lymphedema/CO is very frequent in patients hospitalized in hospital acute wards. It is strongly
associated with obesity, venous insufficiency, and heart failure. Our results strongly suggest a hidden health
care burden and cost linked to CO independently of chronic wounds.
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Background
Epidemiology studies in lymphedema have frequentlyfocused on single patient populations such as those with
cancer rather than on assessing the heterogeneous population
that may suffer with the condition.1 A public health definition
of chronic edema (CO) has been developed and used over the
last decades and this reflects the complex pattern of patients
who may present with the problem.2 The definition defined
below has been adopted in the LIMPRINT study:
‘‘Chronic edema (CO) is a broad term used to describe
edema that has been present for more than three months
and involves one or more of the following areas: limbs,
hands/feet, upper body (breast/chest wall, shoulder,
and back), lower body (buttocks and abdomen), genital
(scrotum, penis, and vulva), head, neck, or face.’’
The term of CO includes those with both primary and
secondary forms of lymphedema, in addition to venous edema
and other factors such as immobility, advanced cancer, obe-
sity, and cardiac and respiratory insufficiency. Within inpa-
tient services, many patients are elderly and will suffer from
multiple comorbidities, for which they are receiving many
different medications that may also promote CO.
The general population is rapidly aging with increasing
comorbidities such as diabetes, immobility, and obesity,
which will further challenge health services in all countries of
the world.3 This will lead to increasing numbers of hospi-
talized patients who are defined as frail with reduced life
expectancy. The concept that CO may be a predictor of frailty
as well as being a risk factor for complications such as cel-
lulitis and wounds is worthy of further investigation.
Defining moderate and severe frailty is particularly chal-
lenging due to lack of agreed definitions.4 Recent National
Institute for Health Care and Excellence (NICE) guidance on
multiple morbidities has highlighted the need to develop new
robust equations to identify patients in primary care or in hos-
pital with reduced life expectancy so that relevant assessments
and interventions can be targeted appropriately. Existing
equations to predict risk of death are based on biased samples,
are insufficiently powered, fail to handle missing data appro-
priately, are poorly reported, or have poor performance to the
extent that NICE has been unable to make a positive recom-
mendation on any tool. The availability of such tools would
allow for the identification of patients at risk of unplanned
hospital admissions or impending death.
Although recent guidance from NICE on multiple mor-
bidities has recommended tools to predict risk of unplanned
hospital admissions, they were unable to identify any equa-
tion to reliably predict all-cause mortality. A recent review by
NICE of 41 studies to predict all-cause mortality found many
methodological limitations, including the omission of key
determinants of death, such as age and sex. In addition, the
sample sizes were frequently small and unrepresentative of
the population.5
Lymphedema management is frequently undertaken in
an outpatient setting, except for dedicated specialist centers that
choose to admit people for intensive periods of treatment (CDT).
There is little awareness of how many patients may have CO
within inpatient services. It is likely that CO will not be the
primary reason for admission and that swelling may be largely
ignored as purely a symptom of a related medical condition such
as cardiac, renal disease, or deep vein thrombosis.
The methodology developed within the LIMPRINT in-
ternational epidemiology included methods to be able to
screen large numbers of patients within a hospital setting.6
Hospital inpatient studies are urgently required to determine
the number of people with CO and its impact on health ser-
vices. There is increasing awareness that CO is associated
with major complications such as cellulitis, which have as-
sociated mortality as well as being a drain on health service
resources.
Cross-sectional based prevalence studies can be under-
taken in defined health care settings such as hospitals or care
homes where the population is fixed over a short time period.
In these settings, a visiting team of researchers can determine
the number of people and clinically assess them, thereby
deriving an accurate estimation of the prevalence in that
setting at a given time point.
Aim: To estimate a point prevalence of CO and wounds as
previously defined in inpatients admitted in hospital in five
different countries within the LIMPRINT International Project.
Methodology
The acronym LIMPRINT stands for Lymphoedema IM-
pact and PRevalence- INTernational. The overall aim was to
determine, using a common methodology, the impact and
prevalence of CO within health services at a national and
international level. This study was undertaken as part of this
international project. Specific methodological issues required
to undertake this study are defined below.
Patient inclusion and exclusion criteria
The study patient inclusion criterion was swelling for
longer than 3 months (CO), with explicit consent for their
data to be transferred into an international database. Patients
met exclusion criteria if they were unwilling or unable to
participate for whatever reason or were receiving end-of-life
care.
Methods
Sampling frameworks were developed for all participating
inpatient hospitals within the study. The screening was un-
dertaken in a single day or over a number of days in larger
facilities. Trained staff screened all patients who consented to
participate, irrespective of their underlying disease or treat-
ment regimen. The presence and chronicity of edema were
confirmed by two methods before CO was judged to be
present (a case).
Confirmation of CO was based on the following two fac-
tors: first, the existence of edema was determined using the
‘‘Pitting Edema Test,’’ which is widely used in clinical
practice and been shown to be valid and reliable.7 Presence of
edema was tested in all body parts, using a standard protocol,
including the upper and lower limbs, trunk, face, and neck.
Second, edema was judged to be chronic if it had been present
for 3 months or more.
Classification of Primary and Secondary Lymphedema
Following the identification of all cases, a further classifi-
cation was made of whether the CO was a primary or secondary
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lymphedema by specialist lymphologists. In those with a
secondary lymphedema, additional suspected factors were
checked, including venous disease and obesity.
Other data collection
A body map was used to record the sites and causes of all
concurrent wounds. Lower and upper mobility status was
defined and information about the history of cellulitis and
treatment were also recorded.
Quality systems
A number of quality systems were used to ensure the
accuracy of data capture. The bed capacity of each ward or
unit was recorded, plus the number of beds occupied, the
number recruited, and the number excluded from consid-
eration and the reasons for this. This enabled the prevalence
to be calculated accurately in inpatient hospital settings.
Double counting of patients who may have moved within
the hospital and be recruited twice was prevented by the
allocation of a patient-specific nonidentifiable number.
Within each facility, quality monitors were established to
check completeness of data from each clinical area before
the research teams left the area and all forms were checked
by a central coordinator.
Data analysis
All information was entered into a bespoke database sys-
tem, which was then downloaded to the statistical packages
being used (SAS, Stata 12.0). Data quality checks were used
to check the internal consistency of the data. The determi-
nation of prevalence was undertaken by dividing the case
positives by the total number of patients who had been as-
sessed. These were presented as percentages. Comparison
of risk factors between groups was undertaken using Chi-
squared analysis, with the results presented as p values.
Results
The LIMPRINT study was undertaken within seven acute
health care facilities in five countries. The different hospitals
participating in the study were two teaching hospitals in
Nottingham (Queen’s Medical Centre [QMC]), Nottingham
City Hospital (City), United Kingdom; four teaching hospi-
tals Saint Eloi, Gui de Chauliac, Lapeyronie, and Arnaud de
Villeneuve in Montpellier, France; two hospitals in Co-
penhagen, Denmark (Bispebjerg and Frederiksberg Hospi-
tal); one general hospital in Canberra, Australia (Calvary
Public Hospital Bruce); and one inpatient oncology ward in
Galway, Ireland (University Hospital Galway).
Proportion of patients in hospital within the whole
population of the study
A total of 1905 patients were included and assessed for CO
and wounds from a total of 3041 eligible hospital occupants.
In two of the hospitals patients who were assessed and found
not to have CO were not interviewed further. This made
FIG. 1. Proportion (%) of patients included from the dif-
ferent settings of care in the nine participating countries of
the LIMPRINT Study.
Table 1. Point Prevalence of Chronic Edema in the Seven Acute Hospital Inpatient Facilities
Facility
Patients with
CO (n)
Patients clinically
assessed in
wards (n)
Prevalence
of CO in
patients clinically
assessed (%)
Total number
of beds
in hospital
(n)
Montpellier, F 215 726 29.6 1150
Canberra, AU 31 113 27.4 113
Ireland 5 45 11.1 62
QMC, UK 155 324 47.8 634
City Hospital, UK 140 245 57.1 490
Bispebjerg Hospital, DK 134 326a 41.1 437
Frederiksberg Hospital, DK 43 126a 34.1 141
Total 723 1905 38.0 3041
Only patients under the Oncology Service (45/62 patients) were assessed for swelling at the University Hospital Galway (total bed capacity 708).
aPatients were assessed in these two hospitals.
CO, chronic edema.
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the total number of patients interviewed as 1630. The main
reason for exclusion was the absence of informed consent
due to cognitive impairment or because the patients were not
in their bedrooms at the time of the census. The participants
recruited in this study represent 13% of the whole LIMPRINT
population (Fig. 1). The prevalence of CO among the patients
who had been included was 723/1905 (38%) (Table 1).
Characteristics of the patients with CO
Mean (SD) age of the patients with CO was 73.0 (15.3)
years and 53.9% were female. CO was secondary in 705
patients (97.5%) with a few patients (18, 2.5%) classified
as primary lymphedema. CO was recognized as lymphe-
dema associated with cancer in only 57 patients (8.1%). Of
the 38 patients with cancer-related swelling, 22 (57.9%)
were cancer treatment-related lymphedema and 17
(44.7%) were at a metastatic stage of the disease.
CO was diagnosed in the lower limbs in 690/716 patients
(96.4%), mainly below the knee, upper limbs in 102 patients
(14.3%), head and neck in 12 patients (1.7%), genitals in 6
patients (0.8%) (1 woman and 5 men), midline, including
head, neck, and genitals, in 47 patients (6.6%), 7 (1.0%) were
localized on the shoulder and upper chest, abdomen in 26/716
patients (3.6%), and buttocks in 22/716 (3.1%) patients.
A total of 52 patients were morbidly obese (7.4%), 213
were obese (30.2%), and 61 (8.7%) were underweight.
Mobility was reduced in most patients being either chair or
bed bound in 89 (12.4%) and 90 (12.5%), respectively. Only
228 (31.7%) patients were walking unaided. Comorbidities
such as diabetes were seen in 184 patients, a known diag-
nosis of heart failure in 259 patients, peripheral arterial
disease in 60 patients, and neurological deficiency in 124
patients, with 292 patients not suffering any of these co-
morbidities (Table 2). Aside from cancer, CO was classified
according to whether the edema was considered to be caused
by other factors. Of the 644 patients with noncancer, sec-
ondary edema venous disease was a contributory cause in
262 patients (40.8%), immobility in 337 patients (52.5%),
obesity in 100 patients (15.6%), and other causes in 222
patients (34.6%).
The duration of CO ranged between less than 6 months in
179 patients (25.4%) to 144 patients (20.45%) for more than
10 years. A history of cellulitis was present in 131 patients
(18.6%) and an episode of any infection was reported in the
previous year in 72 patients (10.2%). Recurrent episodes
were reported once in 44/67 patients (65.7%), where this was
recorded, and at least twice in 23 patients (34.3%). Episodes
of cellulitis were responsible for hospitalization in the past
year in 49/72 patients (68.1%).
Treatment of CO
In total, 698/723 patients diagnosed with CO provided
information on treatments used. Of these, 260 patients
(37.2%) used at least one component of decongestive therapy
with the remaining 430 having no treatment. The most fre-
quent were compression garments in 109 patients (15.6%),
skin care advice in 49 patients (7.0%), multilayer bandaging
in 27 patients (3.9%), wound dressing in the 45 (6.4%) pa-
tients with CO and wounds (6.2%), and antibiotics in 22
patients (3.2%). Massage (9), physiotherapy (16), exercise
advice (14), pneumatic compression (3), cellulitis advice (6),
and psychological support (3) were not frequently reported
by patients nor recorded in the medical records. Professionals
judged the CO was considered controlled by the team of
investigators in 169/718 (23.5%) of the patients and uncon-
trolled in 490/718 (68.2%) patients. There were a further 59
patients in whom the control was unsure.
Prevalence of CO and wounds in hospital
in-patients (whole population)
Wounds were associated with CO in 296/723 (40.9%) of
the patients. The main site of the wound was the lower limb.
As wounds are a recognized source of hospitalization and are
associated with some COs, data were analyzed as prespecified
Table 2. Prevalence of Risk Factors Associated with Lymphedema/Chronic Edema in Hospital Inpatients
with Chronic Edema With and Without Wounds Compared to Those Without
Total population
(n = 1630)
CO only
(n = 427)
CO and wound
(n= 296)
None
(n = 907) p (v2)
Obesity (n= 1294)
Morbidly obese 75 25 (6.1) 27 (9.2) 23 (3.9)
Obese 351 108 (26.2) 105 (35.8) 138 (23.4) <0.001
Normal weight 750 245 (59.5) 134 (45.7) 371 (63.0)
Under weight 118 34 (8.3) 27 (9.3) 57 (9.7)
Lower limb mobility (n = 1287)
Bed bound 151 47 (11.0) 42 (14.3) 62 (10.9)
Chair bound 133 56 (13.1) 34 (11.6) 43 (7.6) <0.001
Walks with aid 437 177 (41.5) 136 (46.4) 124 (21.9)
Walks unaided 566 147 (34.4) 81 (27.7) 338 (59.6)
Comorbiditiesa (n = 1630)
Diabetes Mellitus 291 95 (22.3) 89 (30.1) 107 (11.8) <0.001
Heart Failure 352 148 (34.7) 111 (37.5) 93 (10.3) <0.001
Neurological Deficiency 173 77 (18.0) 47 (15.9) 49 (5.4) <0.001
Peripheral arterial
disease
98 24 (5.6) 36 (12.2) 38 (4.2) <0.001
aNot all comorbidities listed.
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in the study according to the presence of CO whether associ-
ated or not with wounds.
The mean (SD) age was 73.8 (14.4) years in the 427 pa-
tients with CO alone, 72.0 (16.4) in the 292 patients with
both, and 63.6 (19.1) years in the remaining 541 patients with
no wound and no CO ( p< 0.001). Gender was not different
among the three groups. Patients with CO with or without
wounds were more frequently morbidly obese compared to
patients without CO or wounds, more frequently having
mobility problems (65.6% with CO alone, 72.4% CO with
wound, and 32.5% with no CO or wound). Diabetes was three
times more likely in the group with edema present, four times
more likely with heart disease, and five times more likely
with neurological deficiency. Patients with CO and wounds
differ from those with CO alone only in terms of comorbid-
ities known to be associated with wounds such as diabetes
mellitus and peripheral arterial disease.
Finally, patients with CO with and without a wound
had a history of cellulitis for 14.1% and 24.8% of them,
respectively, when those without had very low rates (1.5%)
( p < 0.001) (Table 3). In those who were previously diag-
nosed with cellulitis, cellulitis episodes were frequently re-
sponsible for hospitalization in both groups (CO, and CO and
wound).
Discussion
Lymphedema/CO is a chronic swelling condition that
contributes to disability, chronic wounds, and lost quality of
life. It is associated with risk factors such as obesity, aging,
and cancer treatments, all three increasing at an epidemic
level in Europe.2,8 The overall impact of lymphedema/CO as
a public health problem, however, is underestimated, prin-
cipally due to the lack of diagnosis and epidemiologic data.
These problems pose barriers to optimal management and
prevention of the complications of this lifelong condition,
resulting in disease progression and hospitalization. This
study is the first international study ever performed to assess
the prevalence of lymphedema/CO in patients admitted in
hospital for any medical or surgical reason as a first step of the
identification of the use and cost of health resources allocated
to this condition and their complications.
The results indicate that lymphedema/CO is a very prev-
alent condition with more than 38% (ranging from 11.1 to
57.1%) of the patients showing signs of chronic swelling
when they are admitted in hospital, whatever the initial
medical or surgical indication for hospitalization. This is in
line with the 28.5% prevalence reported in a previous study
conducted in the United Kingdom that included the same
methodology with a prospective assessment.9 The higher rate
that we report might be explained by the involvement of
secondary and tertiary hospitals, including university hospi-
tals, rather than a regionally based hospital.
Data about the prevalence of chronic wounds are available
in the general population and recently estimated at 2.21 per
1000 population.10 Data on the prevalence of chronic wounds
in different health care settings are also available,11 but the
focus is mainly on pressure ulcers in hospital and chronic
wounds within primary care. The health economic burden
that wounds pose to the National Health Service in the United
Kingdom has been estimated,12 as well as in Germany,13
whereas CO has not been recognized to date and therefore
lacks robust evidence. It has to be emphasized that man-
agement of CO is intrinsically linked to wounds particularly
when untreated and this has never been examined before.
The overall prevalence in our study was 38% for the six
main hospitals (where all medical and surgical wards had
been included) and for the one oncology ward that was in-
cluded. However, the prevalence was lowest in the oncology
ward (11.1%).
In this study CO was found to occur twice more frequently
in medical and surgical acute wards than in the oncology
ward. However, caution should be taken due to the relatively
small sample in the oncology ward population. It could be
hypothesized that nutrition and prevention of lymphedema
are key components of cancer management that could result
in a lower prevalence of CO in the oncology ward than in
general medical and surgical wards.14
One of the main reasons explaining why CO had never
been assessed in inpatient facilities before was the require-
ment for a physical examination of each patient, which re-
quires a high number of investigators be made available with
the relevant clinical skills. CO is also a clinical sign that is not
routinely recorded in existing hospital databases. This means
that currently, it is impossible to rely on data from health
systems to assess the burden and cost of care for CO.
A strength of the methodology was the use of lymphology
experts who were responsible for the physical examination
of patients and the examination of medical records. The
expert investigators were frequently required to support
teams of 20–45 general investigators in each hospital. In
the United Kingdom, Denmark, and France, the same eight
Table 3. Prevalence of History of Cellulitis in Patients with Chronic Edema, and Those with Chronic
Edema and Wounds
CO only, N (%) CO and wound, N (%) None, N (%) p (v2)
History of cellulitis (n = 933)
Yes 58 (14.1) 73 (24.8) 3 (1.5) <0.001
No 353 (85.5%) 221 (75.2) 225 (98.7)
Cellulitis within the past 12 months for those with a history of cellulitis (n = 131)
Yes 32 (56.1) 40 (56.3) 1 (33.3) 0.73
No 25 (43.9) 31 (43.7) 2 (66.7)
Hospitalization for those with a history of cellulitis within past 12 months (n = 73)
Yes 19 (59.4) 30 (75.0) — 0.29
No 13 (40.6) 10 (25.0) —
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experts undertook the study in each site, ensuring the har-
monization and validation of the tools that were used to
collect data across the six participating general hospitals.
The oncology ward in Ireland used their local lymphology
experts to support the study.
The limitations of this study were the complexity of
screening patients in busy hospitals. Many were absent from
their beds at the time of recruitment as they were undergoing
tests or surgical or medical interventions. A number of pa-
tients had a cognitive impairment such as dementia which
prevented consent being acquired. It is difficult to estimate
the bias caused by the exclusion of these patients. However, it
is likely to lead to the underreporting of the size of the
problem rather than an inflation of the problem. Patients with
a cognitive impairment are known to suffer from wounds and
poor nutrition, and therefore may have an associated CO.
Thus exclusion of these patients will lead to an underestimate
of the prevalence.
Such a high number of patients with lymphedema/CO raise
the question of whether this is a condition associated with
hospitalization or whether it is a preexisting condition oc-
curring before hospitalization, but contributing to the hospital
admission. The methodology used cannot answer this ques-
tion. However, the profile of patients with CO shares some of
the characteristics of patients with wounds. They are both 10
years older than those without. A substantial number of risk
factors are present in both such as immobility (neurological
deficiency, chair bound, and immobility), and significant
comorbidities such as heart failure, venous disease, and
morbid obesity are shared at the same rate. Contrary to this,
diabetes and peripheral arterial disease were found to be more
important in patients with wounds compared to those with
CO alone. Last, cancer does not appear as the main cause of
lymphedema/CO in hospital inpatient settings.
In line with the frailty profile of these patients is the high rate
of cellulitis events recorded in patients with lymphedema/CO
with and without wounds. Even if logically more prevalent in
patients with wounds (24.8%), the rate was 14.1% in patients
with lymphedema/CO without wounds, when very low in pa-
tients without any CO (1.5%). This means that even if lym-
phedema is not the main reason for hospitalization, it is
associated with significant complications requiring hospitali-
zation such as cellulitis. Moreover, a third of the patients with
lymphedema/CO and half of the patients with wounds had a
history of hospitalization for cellulitis.
This study shows that over a third of patients in inpatient
wards within general hospitals suffer from lymphedema/CO
when physically assessed. There is an increasing emphasis on
identification of frailty particularly within elderly populations.
Results from this study would indicate that CO may prove useful
as a marker of frailty. Further research is needed to examine in
more depth. At the moment, it remains an open question.
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